Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric phase 3 study of deucravacitinib for moderate to severe plaque psoriasis
2022-502519-13-00Phase 3Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of deucravacitinib in plaque psoriasis (3 arms), sponsored by Bristol Myers Squibb. Planned start May 2021; status: authorised.
02
Drugs
deucravacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2022-502519-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502519-13-00.